When grade 3/4 leukopenia and neutropenia occur, the current primary treatment measures involve suspending radiotherapy and administering recombinant human granulocyte colony-stimulating factor (rhG-CSF) via daily subcutaneous injection. This evidence concerns the gene CSF3 and neutropenia.